2025. 1. 21. 16:36ㆍKorean Economy
The JP Morgan Healthcare Conference, now in its 43rd year, is the world's largest investment event for the pharmaceutical and biotech industries. This year, the conference brought together more than 550 companies and over 8,000 participants.
Hugel participated as part of the Asia-Pacific (APAC) track and unveiled its future goals under the vision of "Becoming a Global Industry Leader." By 2028, the company aims to expand the reach of its botulinum toxin products to over 80 countries, HA fillers to more than 70 countries, and cosmetic products to at least 10 countries.
The company outlined specific strategies to achieve these goals: maintaining leadership in the domestic market, accelerating entry into emerging markets such as the Middle East and North Africa, enhancing profitability, and diversifying its product portfolio.
Hugel also detailed its market strategies for key regions. In the U.S., where the company plans to officially launch its botulinum toxin product in the first half of this year, Hugel intends to target the Millennial and Gen Z demographics by leveraging skin clinic channels.
The company also aims to meet the needs of local medical professionals by providing tailored academic content and adopting competitive pricing policies, with the goal of capturing 10% of the aesthetic botulinum toxin market within three years of launch.
For Europe and China, Hugel is targeting a 20–25% market share in their respective botulinum toxin markets by 2027.
During her presentation, Eva Huang, CFO of Hugel, stated, "Hugel will continue to drive growth in the global market by leveraging our leading position in the Korean market, our balanced portfolio of botulinum toxins, fillers, and cosmetic products, and our differentiated corporate value. We are committed to evolving from a domestic leader into a globally top-tier company."